Close monitoring appears to provide results equal to immediate treatment with lower cost and lower risk

JOSLIN DIABETES CENTER

BOSTON – (April 29, 2019) – A change to the approach for treating diabetic macular edema may be on the way, thanks to a study published today in the Journal of the American Medical Association. The study was conducted by the DRCR Retina Network, a multicenter clinical research network funded by the National Eye Institute, part of the National Institutes of Health (NIH). 

The study found that people with diabetic macular edema, who still have good vision, as measured by standard exam with an eye chart, can safely forego immediate treatment of their macular edema as long as they are closely monitored, and treatment begins promptly if vision worsens.

Diabetic macular edema is the most common cause of vision loss among people with diabetic eye disease in the United States. Diabetes can result in the development of leaky blood vessels in the retina–the light-sensing tissue at the back of eye. Diabetic macular edema is the result of fluid build-up in the central area of the retina, called the macula, which is important for sharp vision. Swelling of the macula can distort vision required for reading and driving. 

According to a statement released by the National Eye Institute, the evidence from this study should help physicians and patients navigate a common conundrum in ophthalmology: Treating diabetic macular edema in people who still have good vision too soon may subject them to unnecessary costs and risks associated with treatment. Other patients who get treatment too late might risk losing vision permanently.

“We now know that in patients with good vision and diabetic macular edema, similar to those enrolled in this trial, it’s an acceptable strategy to closely monitor patients, and initiate treatment only if their vision starts to show signs of decline,” said the study’s lead investigator Carl W. Baker, M.D., an ophthalmologist at Paducah (Kentucky) Retinal Center.

The trial included 702 participants with diabetic macular edema and 20/25 vision or better, which is considered normal or near normal vision. At the start of the study, participants were randomly assigned to one of the following three management strategies for one of their eyes: 1) inject into the eye the anti-VEGF agent aflibercept (EYLEA®) as frequently as every four weeks, 2) perform laser photo coagulation, or 3) conduct observation of the participants.

During the two-year study, the detection of visual acuity loss prompted aflibercept injections to be given to the people in the laser or observation groups. Aflibercept injections were thus required among 25% of the laser group and 34% of the observation group. Eyes that started aflibercept injections in the laser and observation groups required a similar number of injections overall compared to the group initially assigned to aflibercept.

The researchers checked participants’ visual acuity throughout the study at regular follow-up visits in retina specialty clinics. Researchers measured visual acuity in the laser and observation groups at eight and 16 weeks after study entry, and then every 16 weeks unless their visual acuity worsened. 

After two years, the percentage of participants whose study eye met a pre-specified threshold for visual acuity loss — one or more lines on an eye chart — did not differ among the groups: 16% of the aflibercept group, 17% of the laser group, and 19% in the observation group. The average visual acuity, which was 20/20 at baseline, remained 20/20 in all three groups at two years.

“Based on what we’ve seen in previous, longer-term studies of people with diabetic macular edema, the visual acuity outcomes observed at the end of this two-year study are likely to be maintained if patients continue regular follow-up and treatment as needed over subsequent years,” said DRCR Retina Network Co-Chair, Jennifer K. Sun, M.D., M.P.H., associate professor of ophthalmology, Joslin Diabetes Center, Harvard Medical School.

“Future technology may do a better job of identifying who might benefit from early treatment, before diabetic macular edema affects vision,” said the director of the study’s coordinating center, Adam R. Glassman, MS, Jaeb Center for Health Research in Tampa. “But for now, close monitoring of diabetic macular edema in patients with good vision is an appropriate initial strategy as long as they are closely followed and subsequently treated if vision worsens.” 

###

The 91-center clinical trial was funded by NEI grants EY14231, EY23207, and the National Institute of Diabetes and Digestive and Kidney Diseases, which is also part of the NIH. ClinicalTrials.gov Identifier: NCT01909791

For more information about diabetic macular edema visit https://nei.nih.gov/health/macular-edema/fact_sheet

Reference:

Baker CW, Glassman AR, Beaulieu WT, Antoszyk AN, Browning DJ, Chalam KV, Grover S, Jampol LM, Jhaveri CD, Melia M, Stockdale CR, Martin DF, Sun JK, for the DRCR Retina Network. “Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macularedema involving the center of the macula and good visual acuity: A randomized clinical trial”. Published online April 29, 2019, JAMA. DOI: 10.1001/jama.2019.5790

NEI leads the federal government’s research on the visual system and eye diseases. NEI supports basic and clinical science programs to develop sight-saving treatments and address special needs of people with vision loss. For more information, visit https://www.nei.nih.gov. 

About Joslin Diabetes Center

Joslin Diabetes Center is world-renowned for its deep expertise in diabetes treatment and research. Joslin is dedicated to finding a cure for diabetes and ensuring that people with diabetes live long, healthy lives. We develop and disseminate innovative patient therapies and scientific discoveries throughout the world. Joslin is an independent, non-profit institution affiliated with Harvard Medical School, and one of only 11 NIH-designated Diabetes Research Centers in the U.S.

For more information, visit http://www.joslin.org or follow @joslindiabetes | One Joslin Place, Boston, MA 617-309-2400